Dabigatran (Generic Pradaxa) Recalled After Cases of Blood Clots And

What Parker Waichman LLP Found

• The FDA recalled specific lots of generic dabigatran after the medication failed impurity and degradation testing.
• The recall affects certain 75 mg and 150 mg blister packs manufactured by Alkem Laboratories Ltd. and distributed by Major Pharmaceuticals.
• Patients should not stop taking blood thinners without first speaking with their healthcare provider.
• Individuals who suffered serious injuries after taking recalled medication may have legal rights depending on the circumstances.
• Pharmacy records, medical records, and the recalled lot number may become important evidence if a lawsuit is filed.

Millions of Americans rely on prescription blood thinners every day to reduce the risk of life-threatening blood clots and strokes. These medications are often prescribed after careful evaluation because they can significantly reduce the chance of serious cardiovascular complications in patients with atrial fibrillation and other medical conditions. When a medication used to prevent strokes and dangerous blood clots becomes the subject of a nationwide recall, patients naturally have questions about their health, their safety, and whether they may have been placed at risk.

The U.S. Food and Drug Administration (FDA) has announced a nationwide recall involving certain lots of dabigatran etexilate capsules, the generic form of Pradaxa. The recalled medication was manufactured by Alkem Laboratories Ltd. and distributed by Major Pharmaceuticals. According to the FDA, the affected lots failed impurity and degradation testing during quality control evaluations. Although the FDA has not yet assigned a recall classification indicating the level of health risk, the failure of these quality standards raises important concerns about the safety and effectiveness of the recalled medication.

Patients should not panic if they possess one of the recalled products. However, they should determine whether their medication is included in the recall and promptly contact their pharmacist or prescribing healthcare provider for guidance. Because blood thinners play a critical role in preventing strokes and blood clots, abruptly stopping treatment without medical supervision can create serious health risks.

Drug recalls involving medications used to prevent life-threatening conditions receive close attention because even minor manufacturing problems can potentially affect patient outcomes. Individuals who suffered serious complications after taking recalled medication may have legal rights depending on the circumstances surrounding their injuries.

What Is Dabigatran and Why Is It Prescribed?

Dabigatran etexilate is an anticoagulant medication commonly prescribed to reduce the formation of harmful blood clots. It belongs to a class of medications commonly referred to as blood thinners, although these drugs do not actually thin the blood. Instead, they reduce the blood’s ability to form dangerous clots that may block circulation.

The medication is frequently prescribed for patients with nonvalvular atrial fibrillation, an irregular heart rhythm that significantly increases the risk of stroke. It may also be prescribed for other conditions involving the prevention or treatment of blood clots.

When functioning properly, dabigatran can help reduce the likelihood of:

• Ischemic stroke
• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Recurrent blood clot formation following treatment

Because these conditions can become life-threatening, patients often depend on uninterrupted anticoagulant therapy. Any issue affecting the quality or effectiveness of these medications deserves careful attention.

Why Were Certain Dabigatran Capsules Recalled?

According to the FDA, the recall was initiated because certain lots failed impurity and degradation testing.

Drug manufacturers must meet strict federal quality standards throughout the manufacturing process. Every batch of medication should contain the correct amount of active ingredient while remaining chemically stable throughout its shelf life. Manufacturers also must ensure medications remain free from unacceptable levels of impurities or degradation products.

Impurity testing evaluates whether unwanted substances are present in a medication.

Degradation testing determines whether the medication maintains its quality and chemical stability over time.

If a drug fails either type of testing, questions arise regarding whether patients may receive medication that does not perform as intended or contains substances that should not be present.

Although the FDA has not yet assigned a specific health hazard classification for this recall, quality failures involving prescription medications require prompt corrective action because patients rely on these medications to prevent serious medical events.

Recalled Dabigatran Products

The nationwide recall includes the following products:

Dabigatran Etexilate Capsules 150 mg

• 60-count blister pack
• Lot Number: 25141583
• Expiration Date: April 30, 2027

Dabigatran Etexilate Capsules 75 mg

• 60-count blister pack
• Lot Number: 25141585
• Expiration Date: April 30, 2027

Dabigatran Etexilate Capsules 75 mg

• 30-count blister pack
• Lot Number: 25141586
• Expiration Date: April 30, 2027

Patients should compare both the dosage and lot number printed on their packaging to determine whether they possess recalled medication.

Why Manufacturing Defects Can Be Dangerous in Blood Thinners

Prescription anticoagulants require extremely precise manufacturing standards.

Even relatively small deviations in potency, purity, or stability may have significant consequences because physicians prescribe these medications based upon carefully determined therapeutic doses.

Potential concerns associated with defective anticoagulant medications may include:

• Reduced effectiveness in preventing blood clots
• Increased risk of stroke
• Increased risk of pulmonary embolism
• Unexpected bleeding complications
• Exposure to impurities
• Medication instability before expiration

Patients often have no way of knowing whether their medication contains impurities or has degraded chemically. They depend entirely upon manufacturers to produce medications that satisfy federal safety requirements.

What Patients Should Do If They Have Recalled Medication

The FDA recommends that patients first determine whether their medication matches one of the recalled lots.

If the medication is included in the recall:

• Contact your pharmacist immediately.
• Notify the healthcare provider who prescribed the medication.
• Ask whether replacement medication is available.
• Continue taking the medication only according to your healthcare provider’s instructions.

Patients should not stop taking anticoagulants without medical advice.

Stopping blood thinner therapy abruptly may substantially increase the risk of stroke or other dangerous blood clot complications. Even missing several doses may increase risk for some patients.

Healthcare providers can determine the safest way to transition patients to replacement medication if necessary.

Potential Injuries Associated With Defective Blood Thinner Medications

Although the FDA has not identified specific injuries associated with this recall, defective prescription medications can potentially contribute to serious medical complications depending upon the nature of the manufacturing defect.

Possible injuries may include:

• Stroke
• Transient ischemic attack
• Deep vein thrombosis
• Pulmonary embolism
• Internal bleeding
• Gastrointestinal bleeding
• Hospitalization
• Permanent disability
• Death

Every situation depends upon the specific facts, including whether the recalled medication actually contributed to a patient’s injury.

Drug Manufacturers Have Important Legal Responsibilities

Pharmaceutical companies have a legal obligation to manufacture medications that meet applicable federal quality standards before distributing them to pharmacies and healthcare providers.

These responsibilities generally include:

• Following current Good Manufacturing Practices (cGMP)
• Conducting appropriate stability testing
• Performing impurity testing
• Maintaining quality control procedures
• Investigating manufacturing deviations
• Removing defective products from distribution when problems are identified

When companies fail to meet these obligations and patients suffer injuries, legal claims may arise under product liability laws.

When a Drug Recall May Lead to a Product Liability Lawsuit

Not every recalled medication results in litigation. However, lawsuits may arise when patients suffer injuries that can be linked to defective pharmaceutical products.

Depending on the facts, legal claims may involve allegations such as:

• Manufacturing defects
• Failure to maintain adequate quality controls
• Negligence
• Failure to warn
• Breach of warranty
• Wrongful death

Attorneys handling pharmaceutical litigation often work with physicians, pharmacologists, manufacturing professionals, and regulatory specialists to determine whether a recalled medication contributed to a patient’s injuries.

Medical records, pharmacy records, prescription history, laboratory testing, and FDA documentation may all become important evidence during these investigations.

Dabigatran Injury Lawsuit FAQs

Can I file a lawsuit if I took recalled dabigatran but have not experienced any health problems?

Generally, a product recall alone does not automatically create a legal claim. Most pharmaceutical product liability lawsuits require evidence that the recalled medication caused an actual injury or measurable damages. However, if you later develop complications that may be related to the recalled medication, an attorney can evaluate whether the recall may be connected to your medical condition.

What if I suffered a stroke while taking one of the recalled lots?

If you experienced a stroke, blood clot, or another serious complication while taking one of the recalled medications, you should preserve your prescription records, medication packaging, and any remaining capsules. These materials may help identify whether your medication came from one of the affected lots. An attorney can investigate whether the recalled medication may have contributed to your injuries.

Should I stop taking my recalled blood thinner immediately?

No. Patients should never discontinue prescription anticoagulants without speaking with the healthcare provider managing their treatment. Suddenly stopping blood thinner therapy can significantly increase the risk of stroke or dangerous blood clots. Your physician or pharmacist can help determine the safest way to replace the recalled medication if necessary.

What evidence may be important in a recalled drug lawsuit?

Evidence often includes pharmacy dispensing records, prescription information, medical records, hospitalization records, diagnostic testing, medication packaging showing the lot number, and documentation identifying the recalled product. Attorneys may also review FDA records, manufacturing information, and quality control documents during their investigation.

Who may be responsible for injuries caused by recalled medication?

Depending on the facts, potentially responsible parties may include the drug manufacturer, distributors, or other companies involved in producing or supplying the medication. Every case requires an individual investigation to determine what happened and whether the recalled product contributed to the patient’s injuries.

Contact Parker Waichman LLP For A Free Case Review

Prescription medications are expected to meet strict safety and quality standards before they reach patients. When a recalled drug may have contributed to a serious injury, patients and their families deserve answers about what happened and whether the manufacturer followed its legal obligations.

Parker Waichman LLP represents individuals and families nationwide in pharmaceutical and defective drug litigation. If you or a loved one suffered a stroke, blood clot, bleeding complication, or another serious injury after taking recalled dabigatran, Parker Waichman LLP can evaluate your potential claim.

The firm offers free consultations, and you pay no attorney’s fees unless compensation is recovered in eligible contingency fee matters. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.

Call 1-800-YOUR-LAWYER (1-800-968-7529) today to discuss your potential case.